Twitter Logo Youtube Circle Icon LinkedIn Icon

United States > Dispute resolution > Product liability, mass tort and class action: pharmaceuticals and medical devices - plaintiff > Law firm and leading lawyer rankings

Editorial

Index of tables

  1. Product liability, mass tort and class action: pharmaceuticals and medical devices - plaintiff
  2. Leading lawyers

Leading lawyers

  1. 1

Who Represents Who

Find out which law firms are representing which Product liability, mass tort and class action: pharmaceuticals and medical devices - plaintiff clients in United States using The Legal 500's new comprehensive database of law firm/client relationships. Instantly search over 925,000 relationships, including over 83,000 Fortune 500, 46,000 FTSE350 and 13,000 DAX 30 relationships globally. Access is free for in-house lawyers, and by subscription for law firms. For more information, contact david.burgess@legal500.com.

CLICK HERE TO VISIT THE WHO REPRESENTS WHO SITE

Burg Simpson Eldredge Hersh & Jardine, P.C.’s Denver-based group has notable experience handling MDLs and mass tort work. Practice head Michael Burg and Seth Katz represented plaintiffs across the US in a bellwether trial arising from claims of injuries sustained through use of the drug Xarelto. Katz has been leading the representation of a number of plaintiffs in mass tort litigation regarding claims of ovarian cancer developed through use of Johnson & Johnson’s talc-based baby powder product. Meghan Quinlivan acted as a member of the plaintiffs’ steering committee in the power morcellators device MDL arising from claims that the devices increased risk of undiagnosed uterine cancer; the MDL was dissolved in 2016 following the settlement of a majority of the cases.

Trusted Advisor - with Finnegan

IP specialist Finnegan detail how their collaborative approach makes for a unique culture which is designed to allow them to work with clients in a way which is cognizant of the challenges facing all companies today.

Within the drug and device arena, Herman, Herman & Katz LLC’s expertise covers high-profile MDLs and class actions, including appellate work. Leonard Davis, Steve Herman, James Klick and of counsel Joseph Kott have been acting for plaintiffs in the Zofran MDL against GSK arising from allegations of defects. Davis, Klick, Kott and Brian Katz continue to represent clients in claims against a number of defendants concerning the drug Fosamax, which is currently on appeal in a number of jurisdictions. Davis, Russ Herman and Maury Herman continue to act for claimants in testosterone replacement therapy litigation brought against AbbVie and a number of other defendants before the Northern District of Illinois. The firm is headquartered in New Orleans.

Based in Pensacola, Florida, Levin Papantonio Thomas Mitchell Rafferty & Proctor, P.A. has impressive capabilities handling personal injury cases, often obtaining jury verdicts across the US. Troy Rafferty was appointed as one of five members of the plaintiffs’ executive committee in the Abilify MDL brought against Bristol-Myers Squibb and Otsuka Pharmaceuticals before the Northern District of Florida. The firm has also been representing plaintiffs across the US in lawsuits against Janssen Pharmaceuticals arising from allegations of kidney injuries caused by use of the drug Invokana. Mike Papantonio is also recommended.

Based in San Francisco, Lieff Cabraser Heimann & Bernstein, LLP has a diverse prescription drug and device practice. Lexi Hazam has been representing various claimants as a member of the plaintiffs’ executive committee in the Abilify MDL. In New York, Wendy Fleishman was appointed to the plaintiffs’ executive committee in the IVC filter blood clot litigation. The firm continues to represent plaintiffs in a number of medical device claims, including Pinnacle hip injury litigation against Johnson & Johnson and its subsidiary DePuy. Key partners include Elizabeth Cabraser and Robert Nelson.

Headed by W Mark Lanier in Houston, The Lanier Law Firm has strong trial capabilities and experience obtaining significant settlements for plaintiffs. In 2016, the firm obtained a federal jury verdict of more than $1bn for six plaintiffs in the Johnson & Johnson Pinnacle hip implant litigation. Richard Meadow was appointed as one of four members to the plaintiffs’ executive committee in the federal MDL brought against Johnson & Johnson concerning ovarian cancer claims arising from use of the company’s talc-based powder products. Lee Cirsch is now at Capstone Law APC.

Headed by co-founder Christopher Seeger, Seeger Weiss LLP’s personal injury practice has deep experience handling drug injury and medical device litigation, including class actions. In 2017, Seeger was appointed as co-lead counsel of the plaintiffs’ steering committee in the Invokana MDL arising from 55 actions alleging that Janssen Pharmaceuticals’ drug causes injuries, such as diabetic ketoacidosis and kidney damage. David Buchanan continues to serve as liaison counsel in coordinated proceedings concerning Accutane, DePuy hip implants and Yaz/Yasmin. Jeffrey Grand has been acting as a member of the plaintiffs’ steering committee regarding seven federal transvaginal mesh product MDLs. All partners are based in New York.

In Washington DC, Ashcraft & Gerel LLP’s pharmaceutical and medical device group continues to handle a broad range of high-profile litigation. In 2016, Michelle Parfitt was appointed to serve as co-lead counsel in the Johnson & Johnson talc-based powder products MDL before the New Jersey District Court following various judgments against the company in other jurisdictions. Parfitt, Christopher Tisi and veteran litigator James Green have been acting for plaintiffs in morcellator lawsuits arising from claims that the surgical devices increase the risk of spreading unsuspected cancerous tissue in hysterectomies and myomectomies. The team is also currently handling negligent misrepresentation and failure to warn claims brought against Bayer regarding the company’s Essure birth control implant.

Beasley, Allen, Crow, Methvin, Portis & Miles, P.C. has notable experience serving in leadership positions in major drug and device MDLs. In 2017, Danielle Mason was appointed to the plaintiffs’ steering committee for the Invokana MDL consolidated in New Jersey federal court regarding allegations that Janssen Pharmaceuticals’ diabetes drug failed to warn for risks associated with its use. Meanwhile, Leigh O’Dell has been serving as co-lead counsel in the Johnson & Johnson talc MDL regarding allegations that the powder product causes ovarian cancer. The team includes the well-regarded Andy Birchfield, Navan Ward and Frank Woodson.

Under the leadership of Arnold Levin, Howard Sedran and Laurence Berman, Levin Sedran & Berman continues to handle a number of dangerous drug lawsuits, as well as medical malpractice and personal injury matters. Michael Weinkowitz continues to act as a committee member in the Xarelto and Yaz/Yasmin litigation. In the medical device arena, the group has been representing plaintiffs across the US in the Mirena IUD lawsuits and in litigation arising from the 2016 recall of the Stryker femoral head hip implant. The firm is headquartered in Philadelphia.

International comparative guides

Giving the in-house community greater insight to the law and regulations in different jurisdictions.

Select Practice Area

The Legal 500 United States - Events

GC Powerlist -
United States

Press releases

The latest news direct from law firms. If you would like to submit press releases for your firm, send an email request to

Legal Developments worldwide

Legal Developments and updates from the leading lawyers in each jurisdiction. To contribute, send an email request to

Press Releases worldwide

The latest news direct from law firms. If you would like to submit press releases for your firm, send an email request to
  • Bär & Karrer Advises CEVA Logistics on its IPO, the anchor investment by CMA CGM and its migration

    CEVA Logistics, one of the world's leading third-party logistics companies, successfully priced its IPO and listed its shares on the SIX Swiss Exchange, where trading commenced on 4 May 2018. With a market capitalization of CHF 1.6 billion and generating gross proceeds of CHF 821 million, this is so far considered as the largest IPO on the SIX Swiss Exchange for 2018. In addition, CMA CGM, the third largest container shipping group in the world, has committed to make a strategic cornerstone investment in CEVA Logistics by purchasing CHF 379 million of mandatory convertible securities which will convert into shares of CEVA Logistics once certain regulatory approvals have been obtained. Simultaneously with the IPO, CEVA Holdings, the former holding company of the CEVA group, migrated from the Marshall Islands to Switzerland by way of a cross-border merger with CEVA Logistic as the surviving company.
  • BAG: Employer not liable for harm caused by vaccine

    Employers who have flu vaccines administered within their company are not liable for any harm that might occur as a result of the vaccine. That was the verdict of the Bundesarbeitsgericht (BAG), Germany’s Federal Labour Court, in a recent ruling.
  • Tax Update

    Cyprus Tax Department has announced that, as of June 1 st 2018 , the following taxes, not bearing interest and charges, can ONLY be paid via JCCsmart (website www.jccsmart.com.cy ) . JCCsmart is a Cyprus portal used to contact payments to various organizations including the Government. This measure follows the successful implementation of the Pay As You Earn (PAYE) tax withheld from employees through JCCsmart.
  • Bär & Karrer Advises on the Financing of the Largest Thermoelectric Plant in Latin America

    Centrais Elétricas de Sergipe S.A. (CELSE) has successfully issued bonds for approx. USD 1 billion equivalent in local currency at a fixed, long-term rate in international capital markets. The innovative bond issue is guaranteed by the Swiss Export Risk Insurance (SERV), the export credit agency of Switzerland. The bonds are part of a financial package to finance the development, design, construction, operation and maintenance of a thermoelectric power plant by CELSE in the state of Sergipe in the northeast region of Brazil. Besides the bond issue for approx. USD 1 billion, the transaction includes a USD 200 million loan from the International Finance Corporation and a financial package of the Inter-American Development Bank in the amount of approx. USD 300 million. Once operational expected for in 2020, CELSE will sell electricity to 26 distribution companies in Brazil, becoming the largest and most efficient thermoelectric plant in Latin America and the Caribbean.
  • BAG: Threats made by employee can justify dismissal with immediate effect

    Employers do not have to accept threats made by employees. These can constitute good cause justifying extraordinary notice of dismissal with immediate effect, as demonstrated by a ruling of the Bundesarbeitsgericht (BAG), Germany’s Federal Labour Court.
  • SyCipLaw is Tier 1 Firm in IP STARS 2018 Rankings

    SyCip Salazar Hernandez & Gatmaitan (SyCipLaw) was once again ranked by Managing IP’s IP STARS 2018 as a Tier 1 firm in Patent and Trademarks/Copyright in the Philippines. In addition, SyCipLaw partners Enrique T. Manuel and Vida M. Panganiban-Alindogan are ranked as Trade mark star – Philippines . Mr. Manuel is also ranked as Patent star – Philippines .
  • Bär & Karrer Advises lastminute.com on Partial Self-Tender Offer

    On 21 September 2017, an extraordinary shareholders' meeting of the SIX Swiss Exchange listed lastminute.com N.V. authorized the board of directors to repurchase up to 33 1/3% of the company's share capital by means of a partial self-tender offer. The resolution adopted under Dutch law contained detailed information, among others regarding the period for which the authorization is granted, the manner in which the shares are repurchased and the price range within which the offer price must be set.
  • New Serbian Law on Foreigners Adopted

    In March 2018, the new Serbian Law on Foreigners was adopted, replacing the 2008 version of this law- in force until recently without any amendments. The new law will enter into force on 3 October 2018.
  • The Serbian Law on Foreign Exchange Amended

    On 20 April 2018, the amendments to the Law on Foreign Exchange (the “Law ”) were adopted and will enter into force on 28 April 2018 . Exceptionally, the application of certain provisions related to the assuming of competencies over foreign exchange control by the National Bank of Serbia is delayed until 1 January 2019.
  • Bär & Karrer Advises Vyaire Medical on its Acquisition of Acutronic Medical Systems

    Vyaire Medical, Inc., a global leader in respiratory care, acquired all shares in the Acutronic Medical Systems group, a Switzerland and Germany-based leader in the design and manufacture of neonatal ventilation equipment.